Cara Therapeutics Inc. (NASDAQ:CARA) price on Thursday, August 26, fall -2.21% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $13.95.
A look at the stock’s price movement, the level at last check in today’s session was $14.27, moving within a range at $13.64 and $14.63. The beta value (5-Year monthly) was 1.31 while the PE ratio in trailing twelve months stood at 133.36. Turning to its 52-week performance, $29.65 and $11.22 were the 52-week high and 52-week low respectively. Overall, CARA moved 20.22% over the past month.
Cara Therapeutics Inc.’s market cap currently stands at around $647.43 million, with investors looking forward to this quarter’s earnings report slated for May 10, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.53, which has seen fiscal year 2021 EPS growth forecast to increase to -$1.91 and about -$0.84 for fiscal year 2022. Per the data, EPS growth is expected to be -1,161.10% for 2021 and 56.00% for the next financial year.
The average forecast suggests down to a -54.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $21.77 million, representing a -83.90% decline on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that CARA is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 7 recommend CARA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CARA’s current price about 7.97% and 4.55% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.57, while 7-day volatility ratio is 12.23% and 7.44% in the 30-day chart. Further, Cara Therapeutics Inc. (CARA) has a beta value of 1.03, and an average true range (ATR) of 1.06. Analysts have given the company’s stock an average 52-week price target of $26.33, forecast between a low of $16.00 and high of $35.00. Looking at the price targets, the low is -14.7% off recent price level in today’s trading while to achieve the yearly target high, it has to move -150.9%. Nonetheless, investors will most likely welcome a -100.72% jump to $28.00 which is the analysts’ median price.
In the market, a comparison of Cara Therapeutics Inc. (CARA) and its peers suggest the former has performed considerably weaker. Data shows CARA’s intraday price has changed -2.21% today and -8.41% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -0.37% so far today and only 14.58% in the past 12 months. Looking at another peer, we see that Flexion Therapeutics Inc. (FLXN) price has dipped -5.44% on the day. However, the stock is -47.26% off its price today a year ago. Moreover, Pfizer Inc. (PFE) is also down -0.26% in today’s trading while keeping a an uptrend of 30.52% over the past year. If we look at the PE ratio, we find that Cara Therapeutics Inc.’s ratio stands at 133.36 compared to Johnson & Johnson’s 26.20. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.37% and -0.19% respectively on the day as seen in early trades.
If we refocus on Cara Therapeutics Inc. (NASDAQ:CARA), historical trading data shows that trading volumes averaged 2.24 million over the past 10 days and 1.37 million over the past 3 months. The company’s latest data on shares outstanding shows there are 50.06 million shares.
The 2.70% of Cara Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 63.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.58 million on Apr 14, 2021, giving us a short ratio of 2.25. The data shows that as of Apr 14, 2021 short interest in Cara Therapeutics Inc. (CARA) stood at 7.16% of shares outstanding, with shares short rising to 3.21 million registered in Mar 14, 2021. Current price change has pushed the stock -5.68% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CARA stock continues to rise going into the next quarter.